loading . . . CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer Abstract. KRAS inhibitors (KRASi) targeting various KRAS mutations have entered clinical trials for pancreatic cancer. Despite promising preliminary clinical responses, most patients relapse due to in... https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-25-1835/767305/CRISPR-Cas9-Screening-Identifies-Resistance